-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhifei Biology (300122.SZ): Recombinant Mycobacterium tuberculosis fusion protein (EC) continues to be included in the national health insurance catalogue
Share
Listen to the news

Zhitong Finance App News, Zhifei Biotech (300122.SZ) announced that the recombinant tuberculosis bacillus fusion protein (EC) (trade name: Yika) developed by Anhui Zhifei Long Kema Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was included in the “2026 National Medical Insurance Catalogue”. This product is suitable for diagnosing Mycobacterium tuberculosis infection and is recommended for infants aged 6 months and above, children and adults under 65 years of age. The inclusion of this product in the “2026 National Medical Insurance Catalogue” will help improve drug accessibility. It will also further develop the synergy of the company's “screening, prevention, and treatment” matrix for tuberculosis products and promote the marketing and sales of this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending